These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11154791)

  • 1. Cost-effectiveness as a criterion for public spending on health: a reply to William Jack's 'second opinion'.
    Musgrove P
    Health Policy; 2000 Dec; 54(3):229-33. PubMed ID: 11154791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public spending on health care: how are different criteria related? A second opinion.
    Jack W
    Health Policy; 2000 Aug; 53(1):61-7. PubMed ID: 10940463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public spending on health care: how are different criteria related?
    Musgrove P
    Health Policy; 1999 Jun; 47(3):207-23. PubMed ID: 10538919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness and the socialization of health care.
    Musgrove P
    Health Policy; 1995; 32(1-3):111-23. PubMed ID: 10156632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allocating health care resources when people are risk averse with respect to life time.
    Hoel M
    Health Econ; 2003 Jul; 12(7):601-8. PubMed ID: 12825211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of public spending on health: does money matter?
    Filmer D; Pritchett L
    Soc Sci Med; 1999 Nov; 49(10):1309-23. PubMed ID: 10509822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Social welfare expenditures, fiscal year 1976.
    Skolnik AM; Dales SR
    Soc Secur Bull; 1977 Jan; 40(1):3-19. PubMed ID: 403620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allocating HIV-prevention resources: balancing efficiency and equity.
    Kaplan EH; Merson MH
    Am J Public Health; 2002 Dec; 92(12):1905-7. PubMed ID: 12453805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the possibility of a bridge between CBA and CEA: comments on a paper by Dolan and Edlin.
    Hansen BO; Hougaard JL; Keiding H; Østerdal LP
    J Health Econ; 2004 Sep; 23(5):887-98. PubMed ID: 15353184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fairness, public expenditure and the cost of new treatments in the UK.
    West PA
    J Health Serv Res Policy; 1999 Jan; 4(1):58-60. PubMed ID: 10345569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marginal benefit incidence of public health spending: evidence from Indonesian sub-national data.
    Kruse I; Pradhan M; Sparrow R
    J Health Econ; 2012 Jan; 31(1):147-57. PubMed ID: 22047653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis.
    Verguet S; Olson ZD; Babigumira JB; Desalegn D; Johansson KA; Kruk ME; Levin CE; Nugent RA; Pecenka C; Shrime MG; Memirie ST; Watkins DA; Jamison DT
    Lancet Glob Health; 2015 May; 3(5):e288-96. PubMed ID: 25889470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Theoretical implications of health economic evaluations in an Austrian context].
    Walter E; Zehetmayr S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):622-7. PubMed ID: 17211767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Going beyond horizontal equity: an analysis of health expenditure allocation across geographic areas in Mozambique.
    Anselmi L; Lagarde M; Hanson K
    Soc Sci Med; 2015 Apr; 130():216-24. PubMed ID: 25721333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramsey waits: allocating public health service resources when there is rationing by waiting.
    Gravelle H; Siciliani L
    J Health Econ; 2008 Sep; 27(5):1143-54. PubMed ID: 18468707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substantial returns to health-care spending: but do we spend too little or too much?
    Buxton MJ
    Value Health; 2006; 9(3):144-5. PubMed ID: 16689707
    [No Abstract]   [Full Text] [Related]  

  • 17. Health gains and financial risk protection: an extended cost-effectiveness analysis of treatment and prevention of diarrhoea in Ethiopia.
    Pecenka CJ; Johansson KA; Memirie ST; Jamison DT; Verguet S
    BMJ Open; 2015 May; 5(4):e006402. PubMed ID: 25941175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normative issues in cost effectiveness analysis.
    Goold SD; Vijan S
    J Lab Clin Med; 1998 Nov; 132(5):376-82. PubMed ID: 9823931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tracking development assistance and government health expenditures for 35 malaria-eliminating countries: 1990-2017.
    Shretta R; Zelman B; Birger ML; Haakenstad A; Singh L; Liu Y; Dieleman J
    Malar J; 2017 Jul; 16(1):251. PubMed ID: 28705160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public financing of health in developing countries: a cross-national systematic analysis.
    Lu C; Schneider MT; Gubbins P; Leach-Kemon K; Jamison D; Murray CJ
    Lancet; 2010 Apr; 375(9723):1375-87. PubMed ID: 20381856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.